Pregled bibliografske jedinice broj: 743420
Serum adiponectin levels in dementia patients and age-matched controls
Serum adiponectin levels in dementia patients and age-matched controls // Clinical Chemistry and Laboratory Medicine / Plebani, Mario (ur.).
Liverpool: Walter de Gruyter, 2014. str. S123-S123 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 743420 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Serum adiponectin levels in dementia patients and age-matched controls
Autori
Dukić, Lora ; Martinić-Popović, Irena ; Šimundić, Ana-Maria
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Clinical Chemistry and Laboratory Medicine
/ Plebani, Mario - Liverpool : Walter de Gruyter, 2014, S123-S123
Skup
The 3rd EFLM-UEMS Congress
Mjesto i datum
Liverpool, Ujedinjeno Kraljevstvo, 07.10.2014. - 10.10.2014
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
adiponectin ; dementia ; hKLK6
Sažetak
Aim: Adiponectin is cytokine produced by adipose tissue and involved in inflammation and insulin resistance. Since adiponectin has neuroprotective effect on hippocampal neurons, we hypothesised that patients suffering from dementia would have lower levels of adiponectin in comparison to healthy population. Aim of our study was to assess the possible difference in adiponectin concentration between patients with Alzheimer’s disease (AD), vascular dementia (VAD) and age-matched controls. Methods: 68 patients with diagnosis of AD (median 75, range 56-94 years) and 71 patient with diagnosis of VAD (median 78, range 58-89 years) were recruited from University Department of Neurology. Control group was divided to 49 cognitively healthy individuals (median 66, range 53-83 years) and 51 individual with diagnosis of mild cognitive impairment (MCI) (median 72, range 53-81 years). Serum concentration of adiponectin was determined using immunoturbidimetric assay Adiponectin (ADPN) (Randox Laboratories Limited, Crumlin, UK). Results: Median adiponectin concentrations for the tested groups were: AD (10.5 ; range 8.4-13.3 μg/mL), VAD (10.6 ; range 7.2-13.4 μg/mL), MCI (10.4 ; range 7.8-14.8 μg/mL) and cognitively healthy controls (8.8 ; range 5.8- 13.3 μg/mL). Kruskall-Wallis statistical test showed no statistically significant differences between the tested groups (P = 0.297). Conclusion: Serum adiponectin concentration does not differ between patients suffering from AD and VAD and healthy individuals without dementia.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
134-1340227-0200 - Upala i udio farmakogenetike u razvoju i ishodu akutnih i kroničnih bolesti (Šimundić, Ana-Maria, MZOS ) ( CroRIS)
Ustanove:
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
- MEDLINE